Cheek Augmentation Surgery (Cheek Implants) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cheek augmentation with implants — also called malar augmentation or submalar augmentation — is a surgical cosmetic procedure in which solid prosthetic implants are placed over the malar (cheekbone) or submalar (mid-cheek) region to restore lost volume, enhance facial projection, and achieve improved facial symmetry. The midface is a central aesthetic unit: prominent, well-defined cheekbones are globally associated with youth, attractiveness, and vitality. As the face ages, subcutaneous fat compartments in the midface descend and atrophy, the malar fat pad thins, and bony resorption occurs, producing a flat, deflated midface contour. Surgical implants provide a permanent structural scaffold that repositions the aesthetic highlight of the cheek and restores a more youthful, three-dimensional facial appearance.

Cheek implant surgery has been performed since the 1950s and has evolved substantially in implant biomaterials, anatomical design, and surgical technique. According to the American Society of Plastic Surgeons, cheek augmentation consistently ranks among the top five facial implant procedures globally. Demand has increased markedly in the context of digital photography and social media, as well as among patients who have undergone significant weight loss. The procedure is also integral to facial feminisation surgery (FFS) and facial masculinisation, where malar projection is a critical gender-affirming feature.

Three anatomical zones are targeted based on aesthetic goals: malar augmentation increases projection of the zygomatic arch (cheekbone prominence), submalar augmentation restores volume to the hollowed mid-cheek below the zygoma, and combined malar-submalar implants address both regions simultaneously — the most frequently performed configuration. Implants are placed in a precisely dissected sub-periosteal pocket (beneath the periosteum directly on bone), which provides the most stable position, minimises migration risk, and shields adjacent soft tissues. The procedure is often combined with rhinoplasty, blepharoplasty, or facelift to achieve comprehensive facial rejuvenation.

Cheek augmentation surgery addresses a spectrum of anatomical and aesthetic concerns relating to midface structure and volume:

• Malar hypoplasia: Congenitally underdeveloped or genetically flat cheekbones producing a flat, featureless midface profile with absent cheek highlights.
• Age-related midface volume loss: Progressive atrophy and descent of the malar fat pad in patients over 40, creating a sunken or gaunt mid-cheek appearance that cannot be adequately corrected with non-surgical fillers alone.
• Post-weight loss facial deflation: Marked volume loss across the midface following bariatric surgery or significant intentional weight reduction.
• Post-traumatic or post-oncological deformity: Cheek flattening resulting from zygomatic fractures inadequately reduced, post-maxillofacial tumour resection, or radiation-induced soft tissue atrophy.
• Facial asymmetry: Structural asymmetry of the zygoma or mid-cheek soft tissues, whether congenital or acquired.
• Facial feminisation surgery (FFS): Enhancement of malar prominence is a standard component of FFS for transgender women seeking softer, more traditionally feminine facial contours.
• Facial masculinisation surgery: High, sharp malar projection and defined zygomatic arches are key masculine facial features augmented in transgender men or cisgender males with flat midfaces.

Ideal candidates for cheek implant surgery present with the following characteristics:

• Adults (18+) with fully developed facial skeletal structure (facial skeleton generally complete by age 17–18)
• Objectively flat or deficient malar prominence documented on three-dimensional photographic analysis or standardised facial anthropometric measurements
• Midface volume loss inadequately corrected by non-surgical dermal fillers (typically >3–5 mL per side required to achieve the desired result)
• Physically healthy without active skin infection, untreated dental disease (dental pathology increases implant infection risk), or immune compromise
• Non-smoker or committed to smoking cessation at least 4 weeks pre-operatively and 4 weeks post-operatively (smoking impairs wound healing and increases infection risk)
• Psychologically stable with realistic, clearly articulated aesthetic goals and understanding that surgery enhances natural features rather than transforming appearance entirely
• No prior extensive midface surgery that has significantly altered the sub-periosteal anatomy (increases dissection difficulty and complication risk)

Contraindications include:

• Active facial acne, skin infection, or herpes labialis outbreak at the time of surgery (risk of implant contamination)
• Untreated or inadequately controlled diabetes mellitus (impaired wound healing and infection susceptibility)
• Immunosuppression from systemic disease or chronic corticosteroid use
• History of keloid scarring (intraoral incisions generally heal without visible scars, but tissue response may be unpredictable)
• Unrealistic aesthetic expectations or body dysmorphic disorder (BDD) — psychiatric screening recommended when BDD is suspected
• Coagulopathy or anticoagulant therapy that cannot be safely discontinued perioperatively

Cheek augmentation may be accomplished surgically or non-surgically, with several implant material and access incision options:

• Solid silicone implants (most common): Medical-grade solid silicone is the gold standard material — pliable, biocompatible, non-absorbable, MRI-compatible, and easy to remove or exchange if needed. Available in anatomically designed shapes: malar (high-cheek projection), submalar (mid-cheek fill), and combined. Sizes and projections are selected from manufacturer systems (Implantech, Stryker, Spectrum Designs) or custom-designed from CT imaging data for complex asymmetries.
• Porous polyethylene (Medpor) implants: A rigid, porous biomaterial that allows fibrovascular ingrowth, creating a biologically integrated implant with very low migration rates. More difficult to remove than silicone if complications arise; used primarily for orbital rim, malar, and post-traumatic reconstructions requiring precise anatomical fitting.
• Expanded polytetrafluoroethylene (ePTFE/Gore-Tex) sheets: Soft, conformable material that integrates with surrounding tissue. Easier to trim intraoperatively for customisation but more challenging to remove completely if revision is needed.
• Custom 3D-printed implants: Derived from pre-operative CT scan data, custom implants are manufactured in titanium or PEEK for complex asymmetric cases, post-traumatic deformities, or patients requiring highly individualised correction. Offer superior anatomical fit but add significant cost and lead time (4–8 weeks production).

Surgical access routes:

• Intraoral (transoral) approach: Incision inside the mouth in the gingivobuccal sulcus (gum-cheek groove), leaving no external scars. The sub-periosteal pocket is dissected with an elevator from this concealed incision. Slight disadvantage: slightly higher infection risk due to oral flora proximity; meticulous antiseptic technique and perioperative antibiotics are mandatory.
• Lower eyelid (transcutaneous or transconjunctival) approach: Used when simultaneous lower blepharoplasty is planned, allowing direct access to the sub-orbital and malar region through the same exposure.
• Temporal approach: Combined with endoscopic browlift, allows midface dissection through the hairline; used in comprehensive facial rejuvenation procedures.

Cheek augmentation surgery offers lasting structural improvement with high documented patient satisfaction:

• Permanent volume restoration: Unlike hyaluronic acid fillers that resorb within 12–18 months and require repeated treatments, solid silicone implants provide a permanent result that does not change with metabolic activity or weight fluctuation.
• High patient satisfaction: Peer-reviewed studies report 85–90% patient satisfaction rates at 1-year follow-up when surgery is performed by a board-certified plastic or maxillofacial surgeon experienced in facial implants. Satisfaction correlates strongly with appropriate implant size selection and sub-periosteal placement.
• Improved facial harmony and proportion: Photographic and anthropometric analysis consistently shows that malar augmentation improves the ogee curve — the S-shaped curve from the lateral brow through the cheek that defines aesthetic midface contour — and enhances the proportional relationship between the midface and lower face thirds.
• Facial rejuvenation: Restoring malar projection addresses several visible ageing stigmata simultaneously: hollowed cheeks, deepened nasolabial folds, and jowl accentuation. Studies in aesthetic surgery literature document an average perceived age reduction of 5–7 years following mid-face implantation combined with fat transfer.
• Complement to other procedures: When combined with rhinoplasty, the altered nose-to-cheek relationship produces dramatically improved facial balance. Combined with lower blepharoplasty, malar augmentation supports the lower eyelid and reduces tear trough prominence.
• Recovery and minimal scarring: The intraoral approach leaves no visible external scars. Most patients are socially presentable (with make-up) within 10–14 days once bruising and swelling subside substantially.

Cheek augmentation is generally safe but carries specific risks that must be communicated prior to consent:

• Implant malposition or asymmetry: The most common reason for revision surgery, occurring in approximately 5–10% of cases. Implant displacement from the sub-periosteal pocket or asymmetric pocket dissection produces visible or palpable irregularity. Revision dissection and repositioning corrects this in the majority of cases.
• Infection: Rates of 1–2% with intraoral approaches using prophylactic antibiotics. Infections may require implant removal, antibiotic therapy, and re-implantation after 3–6 months. Dental procedures should be deferred for 3 months post-implantation and preceded by antibiotic prophylaxis thereafter.
• Sensory changes: Temporary numbness or altered sensation over the cheek (infraorbital nerve territory) occurs in up to 20% of patients due to nerve stretch or bruising during dissection; persistent hypoesthesia in <2% at 12 months.
• Haematoma and seroma: Collection of blood (<2%) or serous fluid (<1%) around the implant; small collections resolve spontaneously, larger ones require aspiration or surgical drainage.
• Bone erosion: Long-term pressure from the implant can cause minor resorption of the underlying zygomatic bone in some patients, typically clinically insignificant but documented on radiographic follow-up in up to 10–15% of long-term cases with firm solid implants.
• Implant extrusion or exposure: Rare (<0.5%) but serious complication requiring implant removal; associated with infection, poor soft tissue coverage, or intraoral wound dehiscence.
• Anaesthetic risks: Standard general anaesthesia risks (aspiration, allergic reaction, cardiovascular events) apply; minimised through pre-operative medical clearance and collaboration with an experienced anaesthetist.

Immediate post-operative period (Days 1–3): Moderate facial swelling, bruising (particularly around the eyes and cheeks), and tenderness are expected and peak at 48–72 hours. A compressive facial garment or taping may be applied to reduce oedema. Cold compresses are applied intermittently for the first 24–48 hours. Patients maintain a liquid or soft diet for 7–10 days following intraoral incisions to minimise stress on suture lines and reduce bacterial contamination. Head elevation (30–45°) during sleep reduces oedema.

Early recovery (Week 1–2): Oral rinses with chlorhexidine gluconate 0.12% are used after each meal for 2 weeks. Sutures dissolve automatically (resorbable intraoral sutures) or are removed at 7–10 days (skin sutures if external approach). By day 10–14, most patients are comfortable appearing in public with cosmetic camouflage. Driving may resume when the patient is off prescription pain medication and can turn the head freely without discomfort, typically at 5–7 days.

Intermediate recovery (Weeks 2–6): Residual swelling and firmness in the cheeks gradually improve. The final implant contour is not fully appreciable until 6–8 weeks as post-operative oedema resolves. Strenuous activity and contact sports are restricted for 6 weeks to prevent implant displacement before the fibrous capsule matures around the prosthesis.

Long-term follow-up: A standard post-operative schedule involves clinical review at 2 weeks, 6 weeks, 3 months, and 12 months. Three-dimensional photographic documentation at baseline and follow-up allows objective outcome assessment. Patients are counselled that the implant does not require replacement unless complications arise, and that normal facial ageing continues around the stable structural scaffold provided by the implant. No routine radiographic surveillance is necessary unless clinical symptoms suggest implant displacement.

Cheek augmentation is classified as an elective cosmetic procedure and is not covered by public health insurance systems or standard private health insurance. Representative costs for bilateral cheek implant surgery:

• United States: USD 6,000–14,000 (surgeon fee, anaesthesia, facility, implants)
• United Kingdom (private): GBP 4,500–9,000
• Australia: AUD 8,000–16,000
• India (Mumbai, Delhi, Bengaluru): USD 1,800–4,000 at JCI/NABH-accredited cosmetic surgery centres
• Thailand (Bangkok): USD 2,500–5,500
• Turkey (Istanbul): USD 2,000–4,500 (packages often include 1–2 nights accommodation)
• South Korea (Seoul): USD 3,000–7,000 (high cosmetic surgery volume with experienced specialist teams)
• Mexico (Monterrey, Tijuana): USD 2,500–5,000

Factors that influence cost:

• Implant material and manufacturer (standard silicone vs. custom 3D-printed implants add USD 2,000–5,000)
• Combination with other procedures (rhinoplasty, blepharoplasty, facelift) — package pricing often reduces combined costs
• Surgeon experience and specialisation (board-certified plastic or maxillofacial surgeon vs. general surgeon)
• Facility type (accredited hospital vs. outpatient surgery centre)
• Geographic location and local market pricing

For patients seeking cheek enhancement without permanent surgical implants, several effective alternatives exist on the continuum from temporary non-surgical to permanent surgical approaches:

• Hyaluronic acid (HA) dermal fillers: Injectable HA products (Juvederm Voluma, Restylane Lyft, Sculptra) placed deep to the dermis or sub-periosteal can augment malar volume, enhance cheek projection, and restore the ogee curve. Effects last 12–24 months, are reversible with hyaluronidase, and carry very low risk. Multiple sessions are required to maintain results, accumulating cost over time. Ideal for patients wanting to preview augmentation before committing to surgery or for mild-to-moderate volume loss.
• Autologous fat transfer (lipofilling): Harvesting the patient's own fat (typically from abdomen or thighs via liposuction) and re-injecting purified fat grafts into the midface. Provides natural-feeling volume restoration without foreign material. Variable take rates (40–60% long-term retention) require overcorrection; approximately 30–50% of patients need a second fat transfer session. Excellent adjunct to or alternative for cheek implants in patients with adequate fat donor sites.
• Calcium hydroxylapatite (CaHA) filler (Radiesse): A bio-stimulatory filler providing immediate volume and stimulating collagen synthesis for 12–18 months of effect. Slightly firmer texture than HA fillers, well-suited to the malar region. Not reversible with hyaluronidase.
• Thread lift (midface suspension): Barbed absorbable sutures (PDO or PLLA) placed subcutaneously to mechanically lift and reposition descended midface soft tissue. Effect is modest and temporary (12–18 months) and less appropriate for patients with primary skeletal deficiency rather than soft-tissue descent.
• Skeletal osteotomies (Le Fort osteotomy, zygomatic osteotomy): For patients with severe skeletal deficiency or dysplastic conditions, orthognathic surgical repositioning of the facial skeleton may be appropriate, though this represents a much more extensive intervention than implant augmentation.
• Contouring with make-up: Cosmetic contouring can simulate cheek projection for photography and social appearance without any medical intervention — a useful adjunct for mild cases.